vTv back from the brink with viable T1D option

6 March 2020

Citing positive Phase II data, industry analyst GlobalData says North Carolina, USA-based vTv Therapeutics (Nasdaq: VTVT) could become “a strong player in the developing market” for type 1 diabetes (T1D) medicines.

vTv had been focused on neurological disorders, exploiting an association between the RAGE receptor and Alzheimer’s disease, but a Phase III failure at the start of 2018 put paid to lead candidate azeliragon, eviscerating the firm’s stock price.

Undeterred, continued research in diabetes yielded a positive Phase II result for the firm’s new frontrunner, TTP399, at the start of February 2020.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK